The Antibody Drug Conjugates (ADC) market size was estimated at USD 5.78 billion in 2023 and is projected to reach USD 24.53 billion in 2030 at a CAGR of 22.94% during the forecast period 2023-2030. Antibody Drug Conjugates (ADC) Market, by Product Type (Adcetris, Kadcyla, and Other Product Types), Application (Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Other Applications), Technology (Cleavable Linker and Non-cleavable Linker), Target Type, End Users and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
Antibody-Drug Conjugates (ADCs) are a class of targeted cancer therapies that combine the speciality of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs. These therapies are designed to specifically target cancer cells while minimizing damage to healthy cells, which can lead to improved treatment efficacy and reduced side effects compared to traditional chemotherapy. Several ADCs have been approved for use in treating various types of cancers, including breast cancer, lymphoma, and certain types of leukaemia. However, its important to note that ADCs may not be suitable for all types of cancers, and their efficacy and safety depend on factors such as the target antigen, the antibody used, the linker technology, and the cytotoxic payload.
The Antibody-Drug Conjugates (ADCs) market is expected to grow during the forecast period. This growth can be attributed to the growing prevalence of cancer, the increasing geriatric population and increasing research and development activities for the development of novel therapeutics. However, factors such as stringent government regulations, high cost of procedures and lack of funding are expected to hamper the growth of the market during the forecast period.
The COVID-19 pandemic has had a significant impact on the ADC market. On the one hand, the disruptions caused by the pandemic in the drug development activities across the healthcare industry including ADCs impacted the market growth negatively. This was due to factors such as the slowdown in clinical trials, reduced funding for research and development, and the diversion of resources to address the COVID-19 pandemic. On the other hand, the demand for effective cancer treatments has increased significantly during the COVID-19 pandemic and this particular factor has contributed to increased demand for cancer drugs including ADCs and factored the market growth.
Request Research Sample Pages: https://www.delvens.com/get-free-sample/antibody-drug-conjugates-adc-market-trends-forecast-till-2030
Delvens Industry Expert's Standpoint
The antibody-drug conjugate (ADC) market is expected to grow during the forecast period. This growth can be attributed to several factors. Firstly, the global cancer burden is increasing, and this is expected to drive the demand for new cancer treatments, including ADCs. Moreover, targeted therapies such as ADCs are becoming increasingly popular as compared to traditional treatment methods such as chemotherapy. In addition, the increasing approval of ADCs by regulatory agencies and development of new ADCs is expected to drive the market further during the forecast period. However, the high cost associated with the development as well as treatment, short shelf life, risk of toxicity and competition from other cancer therapies might hamper the growth of the market during the forecast period.
Key Findings
- Based on product type, the market is segmented into adcetris, kadcyla, and other product types. Kadcyla dominated the market in this segment. Kadcyla specifically targets cancer cells that overexpress the HER2 protein, delivering a potent chemotherapy agent directly to the tumor site.
- Based on application, the market is bifurcated into blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, brain tumor, and other applications. The breast cancer dominated the market in this segment. This is due to increase in the prevalence of breast cancer all around the world.
- Based on technology, the market is segmented into cleavable linker and non-cleavable linker. The cleavable linker ADCs segment dominated the market in this segment. This is due to their increased efficacy and safety.
- Based on target type, the market is bifurcated into cd30 antibodies, her2 antibodies, other target types. The HER2 target type dominated the ADC market in 2022. This is due to the high prevalence of HER2-positive breast cancer and the availability of multiple ADC products for treating this cancer.
- Based on end user, the market is segmented into hospitals and speciality cancer centres, biotechnology and pharmaceutical companies, other end users. Hospitals and specialty cancer centres dominated the market in this segment. This is due to the fact that hospitals and specialty cancer centres are the main providers of cancer treatment and have availability of multiple ADC products for treating this cancer.
- The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. This is due to rising cancer cases and technological developments. Moreover, approvals from regulatory authorities are propelling the market.
To Grow Your Business Revenue, Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/antibody-drug-conjugates-adc-market-trends-forecast-till-2030
Regional Analysis
North America to Dominate the Market
- North America is estimated to account for the largest market share during the forecast period. In North America, rising cancer cases and technological developments are driving the growth of the market.
- Moreover, increasing approvals from regulatory authorities are expected to drive the growth of the market during the forecast period.
Competitive Landscape
- AbbVie Inc.
- ADC Therapeutics SA
- Antikor-M
- AstraZeneca PLC
- Bristol -Myers Squibb
- Catalent Inc.
- F. Hoffmann-La Roche Ltd
- Genentech Inc.
- ImmunoGen Inc.
- Immunomedics Inc.
- Merck & Co., Inc.
- Mersana Therapeutics Inc.
- Novartis AG
- Oxford BioTherapeutics Ltd
- Pfizer Inc.
- Seagen Inc.
- Sorrento Therapeutics Inc.
- Sterling Pharma Solutions Limited
- Takeda Pharmaceutical Company Ltd
Get the Order for the Report: https://www.delvens.com/checkout/antibody-drug-conjugates-adc-market-trends-forecast-till-2030
Recent Developments
- In Feb 2022, Adcentrx Therapeutics and AvantGen entered a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates.
- In March 2022, Sanofi and Seagen Inc. entered a collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets.
Reasons to Acquire
- Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
- Gain authentic and granular data access for the Antibody Drug Conjugates (ADC) Market to understand the trends and the factors involved in changing market situations.
- Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
- In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.
Report Scope
The Antibody Drug Conjugates (ADC) Market is segmented into various segments such as product type, application, technology, target type, end user, and region:
Based on Product Type
- Adcetris
- Kadcyla
- Other Product Types
Based on Application
- Blood Cancer
- Breast Cancer
- Ovary Cancer
- Lung Cancer
- Skin Cancer
- Brain Tumor
- Other Applications
Based on Technology
- Clevable Linker
- Non-cleavable Linker
Based on Target Type
- CD30 Antibodies
- HER2 Antibodies
- Other Target Types
Based on End User
- Hospitals and Speciality Cancer Centers
- Biotechnology and Pharmaceutical Companies
- Other End Users
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact Us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-8638-5055
